Plasma contains metal ions complexed in four forms: those firmly complexed in metalloproteins (the metal ion-donor group bonds being inert), those more loosely complexed to other proteins, those associated with the many low molecular weight ligands present, and those existing as aquated ions. The latter three forms may be considered as being a series of labile complexes which are in competitive chemical equilibrium. (In practice living systems never attain precise equilibrium but their steady state buffered composition is very close to equilibrium in order to attain the maximum efficiency of energy conversion) (Williams 1976) .
The popular mechanism of the copper mobilizing effect of penicillamine is that of reductive chelation whereby monomeric, reduced penicillamine reduces some copper(II) complexes to copper(I). However, we have doubts about the feasibility of copper(I) complexes existing in plasma, primarily becauffe of the oxidative nature of blood and also because of the presence of a great excess of low molecular weight ligands which preferentially bind copper(II). Further, the suggestion of Peisach and Blumberg (1969) that this reductive chelation occurs on the serum albumin overlooks the labile nature of the system; this suggests there should be no kinetic problem in releasing the albumin bound copper provided the correct chelating agent is chosen.
The possibility of dimeric, oxidized, penicillamine being such an agent still has to be considered. Clearly, this is best achieved by a detailed analysis of all the metal-ligand equilibria occurring in the plasma of a patient to whom penicillamine has been administered. However, experimental measurements in vivo are not possible because the complex concentrations are orders of magnitude below those amenable to even the most sophisticated analytical equipment and because there are many thousand species present. Thus simulation of these equilibria using a knowledge of each individual equilibrium system (determined at higher concentrations in vitro) and high speed computers is the only means of estimating these equilibrium concentrations in vivo.
Currently our models involve 5000 complex species and the metal ions Ca2+, Mg2+, Mn2+, Fe3 +, Cu2 +, Zn2 + and Pb2 +. Clearly the absolute concentrations of their metal complexes are controlled by the extent of protein binding, but there are many major difficulties in determining the constants for protein-metal binding, e.g. in defining the numerous complex species that can be produced, in accounting for different binding sites having different metal ion binding capacities and in considering interactions between neighbouring binding sites, &c). However, it has been forcibly argued that the percentage distribution of metal ions among low molecular weight ligands is immune to protein influence and so simulations which omit protein equilibria, pending their exact characterization, can afford reliable information about the metal complexes present. The complete approach has been described elsewhere (May et al. 1976 (May et al. , 1977 .
Results and Discussion
The major low molecular weight complexes of metal ions in the plasma of a healthy human are computed to be those shown in Table 1 . In Table  2 we list the main complexes formed when Dpenicillamine (pen), triethylenetetramine (trien), and for comparative purposes, the well-known chelating drug ethylenediaminetetraacetic acid (EDTA) are administered. The new low molecular weight species occurring in Table 2 obtain the greatest part of their metal content from proteins circulating in plasma (for example, serum albumin), and the remainder at the expense of the complexes listed in Table 1 . Thus, the total low molecular weight content of metal in plasma increases when chelating drugs are administered.
The mobilizing influence of the administered chelating agent is illustrated in Fig 1. In order to avoid the problems of considering different patients having different plasma drug levels, a mobilizing index (MI) can be defined as the factor by which, for a given concentration of chelating agent, the total low molecular weight fraction of the metal ion is increased. It provides a convenient measure of the ability of a chelating agent to mobilize the metal from the labile proteinbound fraction. MI is computed as (the total low molecular weight species in the presence of drug)/ (total low molecular weight species in normal plasma). This ratio effectively eliminates uncertainties arising from metal protein interactiong that would be associated with absolute concentrations. Although all the functions have an upper limit imposed by the total exchangeable metal on the proteins, zinc is atypical in that this limit is rapidly approached and so it is likely to be important. This is because the low molecular weight complexes of zinc in plasma have a total concentration relatively close to the total protein reserve which means that the curves for this metal ion are expected to level off (see Fig 1) . Fig 1 shows that trien medication as low as 10-9M begins to mobilize copper. The agent quoted for reference, EDTA, avidly binds iron (III), zinc(II) and manganese(II), but does not significantly influence copper. This accounts for /g0 (MI) 2 0L -10 the observation by Peisach and Blumberg (1969) that EDTA was ineffective compared with pen, leading to their proposal that pen acts by reducing the copper bound to albumin. It also explains why EDTA is not able to mobilize and thus eliminate sufficient copper to be a satisfactory therapeutic agent for the treatment of Wilson's disease.
Pen, in its reduced form, increases low molecular weight zinc levels at 10-6M and also mobilizes any lead present. Excretion of both these metals is promoted by this chelating agent; pen is, in fact, the treatment of choice for lead poisoning. On the other hand, oxidized pen only feebly binds copper at 10-5M pen and above, ie.. the copper mobilizing influence of pen is 10-4 to 10-5 that of trien. This result cannot be reconciled with the concept that pen competes successfully with albumin for the labile copper in blood plasma. A similar conclusion is expected to apply to the mixed disulphide of pen and cysteine in view of the similarity between the formation constants which characterize the copper-oxidized pen and copper-cystine equilibria.
Thus trien, the agent used as a substitute for pen in treating Wilson's disease patients (Walshe 1975) , undoubtedly exerts its influence via a mobilizing effect upon the labile copper pool. This is in complete agreement with the results of Walshe (1973) , who concluded that the two agents mobilize copper from different body compartments. Indeed, Walshe's findings that trien increases the seAzm copper concentrations while pen does not are also in accord with our proposal that only the former acts specifically as a chelating agent in plasma.
At least two modes of action for pen on copper metabolism are consistent with our results. Possibly, the drug may activate a transport mechanism for concentrating copper from plasma. This is not excluded by the fact that renal rather than hepatic excretion is enhanced by pen therapy, although it does seem somewhat incongruous. More likely, in our opinion, pen could release copper from inert metalloproteins by reduction to copper(I). This copper would not otherwise be available to the labile equilibrium system even in the presence of powerful chelating agents. However, once the copper(I) becomes oxidized to copper(II) in plasma it enlarges the pool which is potentially capable of diffusion across the membrane. Experiments have shown (Walshe 1963 ) that pen is indeed capable of such a role when cvruloplasmin is present, although some other source of copper may be invoked in Wilson's disease patients deficient in this metalloprotein.
It should be noted that the increased concentration of low molecular weight copper produced by these drugs is then available for excretion. However, the rate of removal of copper complexes from plasma and the route which they take may depend upon other factors such as their size and charge as well as upon the amount mobilized.
There are four conclusions arising from this computer simulation study of agents used to reduce copper levels in vivo:
(1) Trien is many orders of magnitude more effective as a copper chelator than pen, the latter being so poor in plasma that we suggest that it exerts its influence elsewhere.
(2) Since two different sites of activity are implicated in (1), we suggest that symbiotic therapy of both pen and trien, or a suitable replacement agent --see (3), might be researched.
(3) The approach should next be extended to the search for other agents that mimic trien and pen. (This project is currently being pursued.) (4) Computer-produced simulations similar to those depicted in Fig 1 
DISCUSSION
Dr Walshe: I do not think that our clinical observations agree with Dr Williams' computer. I know the computer is infallible, but if we give trien to a patient with untreated Wilson's disease there is a sharp rise in his serum copper level within 3 h, at which time the copper begins to come out in the urine. That looks to me like mobilization of tissue copper. If penicillamine is given to such a patient, there is a sharp fall in the serum copper and then the copper comes out in the urine. This would seem to be mobilization of plasma copper, which is exactly the opposite effect. If radio-copper is given to a patient with Wilson's disease and, some hours later when the copper has reached various fluid compartmentsperhaps 24 h later -and is in a fairly stable state, penicillamine or trien is added to the serum in an in vitro system, if it is then sucked through a semipermeable membrane the penicillamine will mobilize more copper than the trien. This again looks to me like the mobilization of albumin copper by the penicillamine, but not by the trien.
Dr Williams: There is, in fact, no discrepancy between your results (Walshe J M, Quarterly Journal of Medicine 42, 441) and our computerbased conclusions. We have suggested that both agents induce cupruresis by enlarging the low molecular weight copper pool. However, they do so by different means. Penicillamine liberates the copper firmly bound to proteins (other than albumin) by a reductive process. The low molecular weight complexes subsequently formed need not necessarily involve penicillamine. Such complexes are neutral and therefore are quite easily dispersed. Trien, on the other hand, draws copper into the serum by chelation and so causes a rise in serum copper. The positive complex so formed is unable to leave this compartment until it is eliminated by the kidneys. Wilson's disease? The reason for the question is obvious, because if such an individual were to marry another heterozygote, 50 % of the children would also have the disease. Dr Walshe: Most of the work on heterozygote detection has been done by Dr Scheinberg and Dr Sternlieb. It is possible to obtain a reasonable degree of certainty, but not 100%. We always screen prospective mates when we can, although most of these girls rush off to get married without asking us first! We always screen any infants that are born. The husband of one girl had only 22 mg per 100 ml of cvruloplasmin, which was some cause for concern. She has now had 3 children who, at the age of seven, five and two, are all running ceruloplasmins of about 5 mg per 100 ml. A liver biopsy was carried out on the eldest child, and we found that the liver copper was about twice the upper limit of normal. which would fit in with the heterozygote state, I am a little apprehensive about it.
Dr R Lovelace (New York): May I ask my old teacher, Dr Walshealthlough Professor Sherlock may wish to comment on itwhether he has ever seen peripheral neuropathy which could be attributed to the copper deposition in Wilson's disease. I ask this question because we have recently seen a patient who appeared not to have sufficient other cause, in terms of diabetes, &c., although he had considerable liver involvement; he had Wilson's disease and definite evidence of both sensory and motor peripheral neuropathy. About 1961 or 1962, when Dr Walshe came to Birmingham to see some patients I was looking after at the time, I remember that some of them had paradoxically impaired and absent reflexes. I wonder whether anyone else has had a similar experience? Professor S Sherlock (London): I have not seen it. Dr Walshe: I must confess that I am so routine in my performances that I have given up testing the sensory nervous system in Wilson's disease patients. I agree that the most complete spectrum of reflex changes is obtained, from those who are completely areflexic to those with grossly exaggerated reflexes. We see an odd type of patient who has what I call sympathetic overactivity, with severe hyperhidrosis and exophthalmoswhich I believe is due to stimulation of the sympathetic nervous system, or irritation thereof. These symptoms get better on treatment with penicillamine. I could not say that I have seen anything which has made me think of a typical peripheral neuropathybut perhaps it is because I do not look for it.
Dr Lovelace: The patient I mentioned had electrical evidence, with low amplitude and absence of evoked responsesmore than just the clinical aspects.
Dr G S Crockett (Kettering): The copper in Wilson's disease must come from the food. Is there any particular food which contains more copper than others, which the patients might be advised not to take? Dr Walshe: Dr Scheinberg is the prime source of information about this. He has listed a number of foods, of which liver, shellfish, chocolates, nuts, mushrooms and whisky are the worst. Mercifully, most patients do not seem to like these foods -I suppose they are mainly children and the only ones which really upset them are the chocolates and the nuts. We have found that white chocolate, whatever it may contain, seems to be copper-free and therefore safe. I think it does not matter too much what they eat if the patients take their penicillamine. If they ask for a diet, that is what I tell thembut, if they do not ask, I do not tell them.
Dr J C Crawhall (Montreal): Did the patient Dr Walshe discussed earlier go through three pregnancies on penicillamine, or was the drug stopped during pregnancy? If she did take it all the time, were the children normal in their development ? Dr Waishe: She did and they were. Details have appeared in the Quarterly Journal of Medicine (1977, 46, (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) . Some patients take penicillamine throughout pregnancy, some do not, but we have had no disasters in terms of any kind of teratogenicity. They are all very nice children that these patients produce.
Dr C B M Warren (Felsted): Has Dr Walshe ever seen anyone over-decoppered, in view of the reports of Menke's syndrome in infants, in whom changes occur in blood vessels and who have these curious changes in their hair? There is a similar condition which is reported to occur in sheep in Australia. Wilson's disease at that time was virtually always fatal. I say 'virtually' because, in a rare instance, it was possible for a patient, stoical beyond belief, to take BAL every day, thereby keeping himself alive. But for most patients (who preferred Wilson's disease to daily BAL injections) this was a disease as fatal as metastatic cancer.
The first thing that Dr Walshe's discoveryor inspirationdid was to turn this fatal disease into one which is effectively curable in perhaps 90% of patients. Indeed, if all of us were more alert in picking up patients while they are still asymptomatic, Wilson's disease could be very close to 100% curableand I do not even think that the 'curable' has to be in quotation marks.
Secondly, his discovery shed light on what was going on. Speculation in the literature about the etiology and pathogenesis of Wilson's disease was abundant. Suggestions had been made that copper was the ultimate villain; Dr Cumings suggested in 1948 that the progression of the illness might be halted if copper could be removed from the patient. But nobody really understood the pathogenesis in terms of the poisoning of enzymes, or cells by copper. From the complicated, long-winded statements of the sort in which all of us in medicine indulge when we do not understand what is going on, a pathogenetic description of Wilson's disease can now be made in half-a-dozen words, and we know precisely what is going on.
Thirdly, through Dr Walshe's efforts the drug became available for other researchers and clinicians to use as their imaginations saw fit. The most remarkable result of this was that another fatal hereditary disease, cystinuria, also became curable, and solely because Dr Walshe had made penicillamine available for someone to be able to give it to patients with cystinuria.
Then there followed a dozen and more conditions, pictured by Dr Lyle on the cover of this meeting's programme, which, in varying degrees, are susceptible to treatment or are ameliorated by penicillamine. Perhaps the most exciting and important of these is that crippling illness, so much more prevalent than any of the other disorders with which we are dealing, rheumatoid arthritis.
Finally, there wasand still isthe impact of this discovery on genetics. Wilson's diseasecopper poisoningoccurs only in people who have inherited a susceptibility to copper pdisoning. Since copper is an element that in relatively small amounts is also essential to life, we have learned over the past 21 years that the avoidance of the Scylla of copper deficiency, and the Charybdis of copper toxicity, Wilson's disease, is not something achieved haphazardly, by chance. Evolution has had to produce complicated biochemical mechanismsand not only for human beingsthat can guide us between these two rocks to a harbour safe from at least one of the myriad assaults made on us by the environment. This is an achievement. If Wilson's disease were not as rare as it is, the recognition that came to Minot, Banting and Fleming shouldand wouldhave come to John Walshe.
